Statin therapy in the prevention of recurrent cardiovascular events a sex-based meta-analysis

Archives of Internal Medicine

Volumn 172, Issue 12, 2012, Pages 909-919

  Gutierrez, Jose ^a   Ramirez, Gilbert ^b   Rundek, Tatjana ^c   Sacco, Ralph L ^c  

^a NEUROLOGICAL INSTITUTE   (United States)

^b FLORIDA INTERNATIONAL UNIVERSITY   (United States)

^c UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ATORVASTATIN; FLUINDOSTATIN; MEVINOLIN; PLACEBO; PRAVASTATIN; SIMVASTATIN;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CEREBROVASCULAR DISEASE; CLINICAL TRIAL (TOPIC); CORONARY ARTERY ATHEROSCLEROSIS; DOSE RESPONSE; HUMAN; ISCHEMIC HEART DISEASE; META ANALYSIS; NEOPLASM; POPULATION RESEARCH; PREVENTIVE MEDICINE; PRIORITY JOURNAL; RECURRENT DISEASE; REVIEW; RISK REDUCTION; SEX DIFFERENCE; SEX RATIO; TREATMENT OUTCOME;

CARDIOVASCULAR DISEASES; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECURRENCE; SECONDARY PREVENTION; SEX FACTORS;

EID: 84862995012     PISSN: 00039926     EISSN: 15383679     Source Type: Journal    
DOI: 10.1001/archinternmed.2012.2145     Document Type: Review

References (63)

1. Sharma VK, Tsivgoulis G, Teoh HL, Ong BK, Chan BP. Stroke risk factors and outcomes among various asian ethnic groups in singapore. J Stroke Cerebrovasc Dis. 2012;21(4):299-304.
2. Ohira T, Shahar E, Chambless LE, Rosamond WD, Mosley TH Jr, Folsom AR. Risk factors for ischemic stroke subtypes: the Atherosclerosis Risk in Communities study. Stroke. 2006;37(10):2493-2498.
3. Sacco RL, Kargman DE, Gu Q, Zamanillo MC. Race-ethnicity and determinants of intracranial atherosclerotic cerebral infarction. The Northern Manhattan Stroke Study. Stroke. 1995;26(1):14-20.
4. Mosca L, Benjamin EJ, Berra K, et al. Effectiveness-based guidelines for the prevention of cardiovascular disease in women-2011 update: a guideline from the american heart association. Circulation. 2011;123(11):1243-1262.
5. Walsh JM, Pignone M. Drug treatment of hyperlipidemia in women. JAMA. 2004;291(18):2243-2252.
6. Kostis WJ, Cheng JQ, Dobrzynski JM, Cabrera J, Kostis JB. Meta-analysis of statin effects in women versus men. J Am Coll Cardiol. 2012;59(6):572-582.
7. Goldstein LB, Amarenco P, Lamonte M, et al; SPARCL Investigators. Relative effects of statin therapy on stroke and cardiovascular events in men and women: secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Study. Stroke. 2008;39(9):2444-2448.
8. Sillesen H, Amarenco P, Hennerici MG, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Atorvastatin reduces the risk of cardiovascular events in patients with carotid atherosclerosis: a secondary analysis of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2008;39(12):3297-3302.
9. Amarenco P, Goldstein LB, Callahan A III, et al; SPARCL Investigators. Baseline blood pressure, low- and high-density lipoproteins, and triglycerides and the risk of vascular events in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Atherosclerosis. 2009;204(2):515-520.
10. Amarenco P, Benavente O, Goldstein LB, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Results of the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial by stroke subtypes. Stroke. 2009;40(4):1405-1409.
11. Goldstein LB, Amarenco P, Zivin J, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels Investigators. Statin treatment and stroke outcome in the Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) trial. Stroke. 2009;40(11):3526-3531.
12. Amarenco P, Bogousslavsky J, Callahan A III, et al; Stroke Prevention by Aggressive Reduction in Cholesterol Levels (SPARCL) Investigators. Highdose atorvastatin after stroke or transient ischemic attack. N Engl J Med. 2006;355(6):549-559.
13. Schwartz GG, Olsson AG, Ezekowitz MD, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA. 2001;285(13):1711-1718.
14. Waters DD, Schwartz GG, Olsson AG, et al; MIRACL Study Investigators. Effects of atorvastatin on stroke in patients with unstable angina or non-Q-wave myocardial infarction: a Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) substudy. Circulation. 2002; 106(13):1690-1695.
15. Kinlay S, Schwartz GG, Olsson AG, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering Study Investigators. High-dose atorvastatin enhances the decline in inflammatory markers in patients with acute coronary syndromes in the MIRACL study. Circulation. 2003; 108(13):1560-1566.
16. Kinlay S, Schwartz GG, Olsson AG, et al; Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study Investigators. Effect of atorvastatin on risk of recurrent cardiovascular events after an acute coronary syndrome associated with high soluble CD40 ligand in the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) Study. Circulation. 2004;110(4):386-391.
17. Schwartz GG, Olsson AG, Szarek M, Sasiela WJ. Relation of characteristics of metabolic syndrome to short-term prognosis and effects of intensive statin therapy after acute coronary syndrome: an analysis of the Myocardial Ischemia Reduction with Aggressive Cholesterol Lowering (MIRACL) trial. Diabetes Care. 2005;28(10): 2508-2513.
18. Olsson AG, Schwartz GG, Szarek M, Luo D, Jamieson MJ. Effects of high-dose atorvastatin in patients > or =65 years of age with acute coronary syndrome (from the myocardial ischemia reduction with aggressive cholesterol lowering [MIRACL] study). Am J Cardiol. 2007;99(5):632-635.
19. Fraley AE, Schwartz GG, Olsson AG, et al; MIRACL Study Investigators. Relationship of oxidized phospholipids and biomarkers of oxidized low-density lipoprotein with cardiovascular risk factors, inflammatory biomarkers, and effect of statin therapy in patients with acute coronary syndromes: Results from the MIRACL (Myocardial Ischemia Reduction With Aggressive Cholesterol Lowering) trial. J Am Coll Cardiol. 2009;53(23):2186-2196.
20. Higgins J, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions. Chichester, England: John Wiley & Sons; 2011.
21. Center for Reviews and Dissemination, University of York. Systematic Reviews: CRD's Guidance for Undertaking Reviews in Health Care. Layerthorpe, York, England: CRD, University of York; 2009.
22. Schachter M. Chemical, pharmacokinetic and pharmacodynamic properties of statins: an update. Fundam Clin Pharmacol. 2005;19(1):117-125.
23. Liem AH, van Boven AJ, Veeger NJ, et al; FLuvastatin On Risk Diminishment after Acute myocardial infarction study group. Effect of fluvastatin on ischaemia following acute myocardial infarction: a randomized trial. Eur Heart J. 2002;23(24):1931-1937.
24. Manisty C, Mayet J, Tapp RJ, et al; ASCOT Investigators. Atorvastatin treatment is associated with less augmentation of the carotid pressure waveform in hypertension: a substudy of the Anglo- Scandinavian Cardiac Outcome Trial (ASCOT). Hypertension. 2009;54(5):1009-1013.
25. Sever PS, Poulter NR, Dahlöf B, et al. Reduction in cardiovascular events with atorvastatin in 2,532 patients with type 2 diabetes: Anglo-Scandinavian Cardiac Outcomes Trial-lipid-lowering arm (ASCOT-LLA). Diabetes Care. 2005;28(5):1151-1157.
26. Sever PS, Dahlöf B, Poulter NR, et al; ASCOT Investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Drugs. 2004;64(Suppl 2):43-60.
27. Sever PS, Dahlöf B, Poulter NR, et al; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial-Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003;361(9364):1149-1158.
28. Tonkin AM. Management of the Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) study after the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1995;76(9):107C-112C.
29. Tonkin AM, Colquhoun D, Emberson J, et al. Effects of pravastatin in 3260 patients with unstable angina: results from the LIPID study. Lancet. 2000;356(9245):1871-1875.
30. Marschner IC, Colquhoun D, Simes RJ, et al; Long- Term Interventionwith Pravastatin in Ischemic Disease (LIPID) Study; LIPID Study Investigators. Long-term risk stratification for survivors of acute coronary syndromes. Results from the Longterm Intervention with Pravastatin in Ischemic Disease (LIPID) Study. J Am Coll Cardiol. 2001;38 (1):56-63.
31. MacMahon S, Sharpe N, Gamble G, et al; LIPID Trial Research Group. Effects of lowering average of below-average cholesterol levels on the progression of carotid atherosclerosis: results of the LIPID Atherosclerosis Substudy. Circulation. 1998; 97(18):1784-1790.
32. Keech A, Colquhoun D, Best J, et al; LIPID Study Group. Secondary prevention of cardiovascular events with long-term pravastatin in patients with diabetes or impaired fasting glucose: results from the LIPID trial. Diabetes Care. 2003;26(10):2713-2721.
33. Hague W, Forder P, Simes J, Hunt D, Tonkin A; LIPID Investigators. Effect of pravastatin on cardiovascular events and mortality in 1516 women with coronary heart disease: results from the Long- Term Interventionwith Pravastatin in Ischemic Disease (LIPID) study. Am Heart J. 2003;145(4): 643-651.
34. Colquhoun D, Keech A, Hunt D, et al; LIPID Study Investigators. Effects of pravastatin on coronary events in 2073 patients with low levels of both lowdensity lipoprotein cholesterol and high-density lipoprotein cholesterol: results from the LIPID study. Eur Heart J. 2004;25(9):771-777.
35. The Long-Term Intervention with Pravastatin in Ischaemic Disease (LIPID) Study Group. Prevention of cardiovascular events and death with pravastatin in patients with coronary heart disease and a broad range of initial cholesterol levels. N Engl J Med. 1998;339(19):1349-1357.
36. Design features and baseline characteristics of the LIPID (Long-Term Intervention with Pravastatin in Ischemic Disease) Study: a randomized trial in patients with previous acute myocardial infarction and/or unstable angina pectoris.AmJ Cardiol. 1995;76(7):474-479.
37. Waters D, Higginson L, Gladstone P, Boccuzzi SJ, Cook T, Lespérance J. Effects of cholesterol lowering on the progression of coronary atherosclerosis in women. A Canadian Coronary Atherosclerosis Intervention Trial (CCAIT) substudy. Circulation. 1995;92(9):2404-2410.
38. Waters D, Higginson L, Gladstone P, Kimball B, Le- May M, Lespérance J. Design features of a controlled clinical trial to assess the effect of an HMG CoA reductase inhibitor on the progression of coronary artery disease. Canadian Coronary Atherosclerosis Intervention Trial Investigators Montreal, Ottawa, and Toronto, Canada. Control Clin Trials. 1993;14(1):45-74.
39. Design and baseline results of the Scandinavian Simvastatin Survival Study of patients with stable angina and/or previous myocardial infarction. Am J Cardiol. 1993;71(5):393-400.
40. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344(8934):1383-1389.
41. Baseline serum cholesterol and treatment effect in the Scandinavian Simvastatin Survival Study (4S). Lancet. 1995;345(8960):1274-1275.
42. Kjekshus J, Pedersen TR. Reducing the risk of coronary events: evidence from the Scandinavian Simvastatin Survival Study (4S). Am J Cardiol. 1995; 76(9):64C-68C.
43. Pyǒrälä K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care. 1997;20(4):614-620.
44. Miettinen TA, Pyörälä K, Olsson AG, et al. Cholesterol- lowering therapy in women and elderly patients with myocardial infarction or angina pectoris: findings from the Scandinavian Simvastatin Survival Study (4S). Circulation. 1997;96(12): 4211-4218.
45. Pedersen TR, Olsson AG, Faergeman O, et al. Lipoprotein changes and reduction in the incidence of major coronary heart disease events in the Scandinavian Simvastatin Survival Study (4S). Circulation. 1998;97(15):1453- 1460.
46. Ballantyne CM, Olsson AG, Cook TJ, Mercuri MF, Pedersen TR, Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation. 2001;104(25):3046-3051.
47. Wilhelmsen L, Pyörälä K, Wedel H, Cook T, Pedersen T, Kjekshus J. Risk factors for amajor coronary event after myocardial infarction in the Scandinavian Simvastatin Survival Study (4S). Impact of predicted risk on the benefit of cholesterol-lowering treatment. Eur Heart J. 2001;22(13):1119-1127.
48. Shepherd J, Blauw GJ, Murphy MB, et al; PROSPER study group, PROspective Study of Pravastatin in the Elderly at Risk. The design of a prospective study of Pravastatin in the Elderly at Risk (PROSPER). Am J Cardiol. 1999;84(10):1192-1197.
49. Shepherd J, Blauw GJ, Murphy MB, et al; PROSPER study group. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet. 2002;360(9346):1623-1630.
50. Lewis SJ, Sacks FM, Mitchell JS, et al. Effect of pravastatin on cardiovascular events in women after myocardial infarction: the cholesterol and recurrent events (CARE) trial. J Am Coll Cardiol. 1998;32(1):140-146.
51. Pitt B, Mancini GB, Ellis SG, Rosman HS, Park JS, McGovern ME. Pravastatin limitation of atherosclerosis in the coronary arteries (PLAC I): reduction in atherosclerosis progression and clinical events. PLAC I investigation. J Am Coll Cardiol. 1995;26(5):1133-1139.
52. Riegger G, Abletshauser C, Ludwig M, et al. The effect of fluvastatin on cardiac events in patients with symptomatic coronary artery disease during one year of treatment. Atherosclerosis. 1999;144(1):263-270.
53. Nguyen JT, Berger AK, Duval S, Luepker RV. Gender disparity in cardiac procedures and medication use for acute myocardial infarction. Am Heart J. 2008;155(5):862-868.
54. Owens GM. Gender differences in health care expenditures, resource utilization, and quality of care. J Manag Care Pharm. 2008;14(3)(Suppl):2-6.
55. Morton-Rias D, McFarlane SI. Gender disparity in the management and outcomes of cardiovascular risk factors in diabetic and hypertensive patients: a cross-cultural phenomenon. J Postgrad Med. 2008;54(4):250-251.
56. Chou AF, Wong L, Weisman CS, et al. Gender disparities in cardiovascular disease care among commercial and medicare managed care plans. Womens Health Issues. 2007;17(3):139-149.
57. Roger VL, Go AS, Lloyd-Jones DM, et al; American Heart Association Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics--2011 update: a report from the American Heart Association. Circulation. 2011; 123(4):e18-e209.
58. Faludi AA, Aldrighi JM, Bertolami MC, et al. Progesterone abolishes estrogen and/or atorvastatin endothelium dependent vasodilatory effects. Atherosclerosis. 2004;177(1):89-96.
59. Wang X, Magkos F, Mittendorfer B. Sex differences in lipid and lipoprotein metabolism: it's not just about sex hormones. J Clin Endocrinol Metab. 2011;96(4):885-893.
60. Sacks FM,Walsh BW. Sex hormones and lipoprotein metabolism. Curr Opin Lipidol. 1994;5(3):236-240.
61. Koh KK, Cardillo C, Bui MN, et al. Vascular effects of estrogen and cholesterol-lowering therapies in hypercholesterolemic postmenopausal women. Circulation. 1999;99(3):354-360.
62. Rundek T. Do women have worse outcome after stroke caused by intracranial arterial stenosis? Stroke. 2007;38(7):2025-2027.
63. Cone C, Murata G, Myers O. Demographic determinants of response to statin medications. Am J Health Syst Pharm. 2011;68(6):511-517.